Although KIT or PDGFRA mutations are infrequent in CML, there is emerging evidence that suggests a link between Imatinib resistance and mutations in the activation loops of these genes, signifying the wider importance of mutation profiling in tailoring treatment strategies across different cancer types [32]. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.